32.85
-0.43
(-1.29%)
At close: April 15 at 4:00:02 PM EDT
32.30
-0.55
(-1.67%)
Pre-Market: 4:57:51 AM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 32,470 | 5 |
| Sales | 100,925 | 12 |
| Net Shares Purchased (Sold) | -68,455 | 17 |
| Total Insider Shares Held | 6.6M | -- |
| % Net Shares Purchased (Sold) | -1.00% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| DAMBKOWSKI CARL Officer | Sale at price 35.56 - 37.59 per share. | Direct | 139,801 | Apr 2, 2025 |
| HENDERSON MICHAEL THOMAS Chief Executive Officer | Sale at price 29.98 - 30.62 per share. | Direct | 301,511 | Mar 5, 2025 |
| DAMBKOWSKI CARL Officer | Sale at price 30.48 per share. | Direct | 48,463 | Mar 5, 2025 |
| HENDERSON MICHAEL THOMAS Chief Executive Officer | Sale at price 40.58 per share. | Direct | 608,700 | Feb 5, 2025 |
| DAMBKOWSKI CARL Officer | Sale at price 40.69 per share. | Direct | 143,229 | Feb 5, 2025 |
| DAMBKOWSKI CARL Officer | Conversion of Exercise of derivative security at price 22.86 per share. | Direct | 18,174 | Feb 5, 2025 |
| HENDERSON MICHAEL THOMAS Chief Executive Officer | Conversion of Exercise of derivative security at price 22.86 per share. | Direct | 194,310 | Jan 31, 2025 |
| HENDERSON MICHAEL THOMAS Chief Executive Officer | Sale at price 48.72 - 49.38 per share. | Direct | 732,693 | Jan 8, 2025 |
| DAMBKOWSKI CARL Officer | Sale at price 46.42 - 47.92 per share. | Direct | 191,740 | Jan 2, 2025 |
| DAMBKOWSKI CARL Officer | Conversion of Exercise of derivative security at price 22.86 per share. | Direct | 31,090 | Jan 2, 2025 |
| MCKENNA MARK C Director | Purchase at price 49.02 - 49.85 per share. | Direct | 990,775 | Dec 12, 2024 |
| DAMBKOWSKI CARL Officer | Sale at price 48.62 - 50.00 per share. | Direct | 221,363 | Dec 11, 2024 |
| DAMBKOWSKI CARL Officer | Conversion of Exercise of derivative security at price 22.86 per share. | Direct | 41,491 | Dec 11, 2024 |
| HENDERSON MICHAEL THOMAS Chief Executive Officer | Sale at price 46.50 - 47.19 per share. | Direct | 698,654 | Dec 4, 2024 |
| DAMBKOWSKI CARL Officer | Sale at price 46.07 per share. | Direct | 307,057 | Dec 4, 2024 |
| HENDERSON MICHAEL THOMAS Chief Executive Officer | Sale at price 59.17 - 59.94 per share. | Direct | 888,320 | Nov 6, 2024 |
| DAMBKOWSKI CARL Officer | Sale at price 58.91 - 59.96 per share. | Direct | 394,041 | Nov 6, 2024 |
| HENDERSON MICHAEL THOMAS Chief Executive Officer | Sale at price 56.07 - 56.74 per share. | Direct | 2,249,307 | Oct 2, 2024 |
| DAMBKOWSKI CARL Officer | Sale at price 56.16 - 56.86 per share. | Direct | 374,954 | Oct 2, 2024 |
| HENDERSON MICHAEL THOMAS Chief Executive Officer | Sale at price 47.28 - 48.23 per share. | Direct | 1,904,841 | Sep 4, 2024 |
| DAMBKOWSKI CARL Officer | Sale at price 47.49 - 48.06 per share. | Direct | 316,969 | Sep 4, 2024 |
| HENDERSON JANE Chief Financial Officer | Sale at price 48.26 per share. | Direct | 289,560 | Aug 23, 2024 |
| HENDERSON MICHAEL THOMAS Chief Executive Officer | Sale at price 40.40 - 42.17 per share. | Direct | 1,624,764 | Aug 7, 2024 |
| DAMBKOWSKI CARL Officer | Sale at price 40.47 - 42.56 per share. | Direct | 298,336 | Aug 7, 2024 |
| HENDERSON MICHAEL THOMAS Chief Executive Officer | Sale at price 37.26 per share. | Direct | 558,900 | Jul 5, 2024 |
| DAMBKOWSKI CARL Officer | Sale at price 37.29 - 38.16 per share. | Direct | 225,418 | Jul 3, 2024 |
| FAIRMOUNT FUNDS MANAGEMENT LLC Director | Purchase at price 17.00 per share. | Indirect | 49,999,992 | Jul 13, 2023 |
| SHAH NIMISH P Director | Purchase at price 17.00 per share. | Indirect | 29,750,000 | Jul 13, 2023 |
Related Tickers
SYRE Spyre Therapeutics, Inc.
12.71
-2.38%
DNTH Dianthus Therapeutics, Inc.
19.21
+2.67%
ORKA Oruka Therapeutics, Inc.
8.56
+5.16%
MLTX MoonLake Immunotherapeutics
36.77
+2.85%
VRDN Viridian Therapeutics, Inc.
12.80
-3.76%
NUVL Nuvalent, Inc.
70.78
+1.11%
COGT Cogent Biosciences, Inc.
4.8700
+6.33%
TRML Tourmaline Bio, Inc.
14.93
+5.96%
MLYS Mineralys Therapeutics, Inc.
13.88
-0.29%
KYMR Kymera Therapeutics, Inc.
25.46
+0.12%